More tools:
Markets
·
Screener
·
Research
·
Chat
HEMAB THERAPEUTICS HOLDINGS (COAG) Financial Statements
HEMAB THERAPEUTICS HOLDINGS
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG021LKFWY3
US
45.27
▲ 16.03 (54.82%)
As of 2026-09-09
1M
6M
1Y
Valuation
Market Cap
$2.1B
Enterprise Value
—
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
—
EBITDA
—
Diluted EPS (TTM)
—
EBITDA Margin
—
Net Debt
—
Trading Information
Previous Close
29.24
Day's Range
26.81 – 29.47
52-Week Range
23.00 – 36.61
Volume
1.5M
Avg Volume
234.1K
Share Statistics
Shares Outstanding
46.7M
Employees
—
Exchange
US
Listed
—
Share count as of July 31, 2026
View
Income Statement
Balance Sheet
Cash Flow
Key Metrics
Valuation
Comparable Companies
Notes & Facts
DCF Model
Earnings Calls
Guidance
Presentations
Detail
Standard
Detailed
Period
Annual
Quarterly
TTM
Loading Income Statement…
Key questions about HEMAB THERAPEUTICS HOLDINGS (COAG)
What is HEMAB THERAPEUTICS HOLDINGS's Market Cap?
HEMAB THERAPEUTICS HOLDINGS's Market Cap is $2.1B, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Subscribe
Income Statement
(in thousands of USD, except per-share data)
Source: Akyla.ai
Line Item
Jun 30, 2026
Mar 31, 2026
Jun 30, 2025
Mar 31, 2025
Operating expenses:
Research and development
20,336.0
19,461.0
General and administrative
5,743.0
4,151.0
Total operating expenses
26,079.0
23,612.0
Loss from operations
(26,079.0)
(23,612.0)
Other income (expense), net:
Interest income
2,858.0
1,219.0
Other (expense) income, net
(832.0)
(282.0)
Total other income, net
2,026.0
937.0
Loss before income tax expense
(24,053.0)
(22,675.0)
Income tax (expense) benefit
(97.0)
(12.0)
Net loss
(24,150.0)
(22,687.0)
Net loss per share, basic
(0.80)
(23.98)
Net loss per share, diluted
(0.80)
(23.98)